Single-agent chemotherapy of brain tumors. A five-year review.
Single-agent chemotherapy of brain tumors. A five-year review.
复制标题
脑肿瘤的单药化疗。
DOI：
10.1001/archneur.1976.00500110007002
复制
发表时间：
1976
影响因子：
--
通讯作者：
K. Enot
中科院分区：
文献类型：
--
作者：
C. Wilson;P. Gutin;E. Boldrey;D. Drafts;V. Levin;K. Enot
脑肿瘤有效的单一化疗药物的鉴定必须先于多种药物组合的合理使用。在1968年开始的2期试验中，158名患有脑内肿瘤（大多数是复发性恶性星形细胞瘤）的患者被认为是可评估的。使用更有效药物的大型试验产生了这些结果：卡莫司汀（BCNU）的反应率为47%，中位持续时间为9个月;洛莫司汀（CCNU）为44%，中位持续时间为6个月;盐酸丙卡巴肼为52%，中位持续时间为6个月;卡莫司汀和硫酸长春新碱联合用药为44%，中位持续时间仅为4个月;和BIC（5-[3，3-双（2-氯乙基）-1-三氮烯]咪唑-4-甲酰胺），38%，中位持续时间为5个月。未发现糖皮质激素给药会使应答频率发生偏倚。47名患者，其中26人对最初的药物有反应，接受了第二种药物。在26名可评估的患者中，只有4名对第二种药物有反应。
Identification of effective single chemotherapeutic agents for brain tumors must precede the rational use of multiple drug combinations. In phase 2 trials beginning in 1968, 158 patients with intrinsic brain tumors (mostly recurrent malignant astrocytomas) were considered evaluable. The larger trials with more effective drugs produced these results: carmustine (BCNU) response rate, 47%, with median duration of nine months; lomustine (CCNU), 44%, with median duration of six months; procarbazine hydrochloride, 52%, with median duration six months; carmustine and vincristine sulfate combined, 44%, with median duration of only four months; and BIC (5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide), 38%, with median duration of five months. Administration of glucocorticoids was not found to bias the frequency of response. Forty-seven patients, 26 of whom had responded to the initial drug, received a second drug. Among 26 patients who were evaluable, only four responded to the second drug.